Ongoing Trials Investigate Amivantamab Combinations for EGFR+ NSCLC
January 7th 2023Melina E. Marmarelis, MD, reports the study design of the Chrysalis-2 trial and ongoing trials researching the combination of amivantamab and lazertinib in patients with EGFR-mutated advanced non–small cell lung cancer.